[New Classification for Advanced Colorectal Cancer Using CancerPlex®Genomic Tests]

Area of Science:

• Oncology
• Genomics
• Precision Medicine

Background:

• Colorectal cancer (CRC) treatment has advanced with targeted drugs.
• KRAS mutations are linked to resistance against epidermal growth factor receptor (EGFR) therapies.
• Previous anti-EGFR monotherapy response rates for CRC were below 30%.

Purpose of the Study:

• To analyze gene mutations in Stage IV CRC patients using genomic testing (CancerPlex®).
• To identify patient subgroups that may benefit from specific targeted therapies.
• To explore the potential for developing precision medicine approaches in advanced CRC.

Main Methods:

• Retrospective review of 112 Stage IV CRC patients' medical records (2007-2015).
• Genomic analysis using CancerPlex® to identify gene mutations.
• Cluster analysis of 110 non-hypermutated Japanese CRC patients to identify distinct groups.

Main Results:

• Six distinct patient groups were identified through cluster analysis.
• Patients with all wild-type actionable genes demonstrated significant benefit from anti-EGFR therapies.
• Genomic information can guide treatment decisions for advanced CRC.

Conclusions:

• Genomic profiling using CancerPlex® can stratify advanced CRC patients.
• Tailoring anti-EGFR therapy based on genetic profiles improves treatment efficacy.
• Precision medicine strategies are crucial for optimizing cost-effectiveness and outcomes in advanced CRC treatment.